Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.

Martin Begemann Oliver Gross Dominik Wincewicz Ruediger Hardeland Vinicius Daguano Gastaldi Eduard Vieta Karin Weißenborn Kamilla Woznica Miskowiak Onnen Moerer Hannelore Ehrenreich

Published in: Molecular medicine (Cambridge, Mass.) (2021)

Substitution of EPO may-among other beneficial EPO effects in severe COVID-19-circumvent downstream consequences of the 'hypoxia paradox'. A double-blind, placebo-controlled, randomized clinical trial for proof-of-concept is warranted.

Keyphrases

coronavirus disease
sars cov
double blind
placebo controlled
early onset
endothelial cells
respiratory syndrome coronavirus
molecular docking